Results 151 to 160 of about 118,413 (285)

Does out of Hours Endoscopic Retrograde Cholangiopancreatography Lead to Higher Pancreatitis and Hospitalization Rates?

open access: yesANZ Journal of Surgery, EarlyView.
The aim of this study was to determine if ERCP related morbidity is higher if performed out of workinghours. Contemporaneously collected data patients undergoing ERCP at an Australian hospital were analysed. No difference was found in rates of post‐ERCP pancreatitis (PEP) in patients undergoing out of hours ERCP compared with in hours ERCP (p = 0.759).
Hasib Ahmadzai   +4 more
wiley   +1 more source

Atorvastatin-Associated Acute Pancreatitis: A Case Report. [PDF]

open access: yesAm J Case Rep
Alshammari F, Alharbi A, Alshammari RA.
europepmc   +1 more source

Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?

open access: yesActa Ophthalmologica, EarlyView.
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs   +12 more
wiley   +1 more source

Endocrine Abnormalities and Growth Pattern in Single Large‐Scale Mitochondrial DNA Deletion Syndromes

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To assess the prevalence of endocrine disorders and investigate growth patterns in single large‐scale mitochondrial DNA deletion syndromes (SLSMDs). Methods A retrospective study of all children with SLSMD who attended Sheba Medical Center, Israel, from February 2017 to September 2024.
Ayman Daka   +7 more
wiley   +1 more source

Atypical presentation of painless acute pancreatitis: A case report. [PDF]

open access: yesWorld J Clin Cases
Sargon K   +5 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy